The new treatment is developed by the Accelerated Evolution Biotechnologies pharmaceutical laboratory under the direction of the CEO, Dr. Ilan Morad, according to the report.
"We believe we will offer a complete cancer treatment a year"he said Dan Aridor, Chairman of the Board of Directors. "Our cancer drug will be effective from the first day, it will last for several weeks and will have minimal side effects or none at much lower costs than most other treatments on the market",
The treatment, called "MuTaTo," will use a combination of anticancer peptides and a toxin that specifically kills cancer cells.
Treatment will eventually be individualized and patients receive a specific cocktail of drugs by type of cancer, Morad told reporters.
Despite the importance of the announcement, some voices question the functioning of the new treatment, for example, considering that it was tested only in mice.
In this regard, the Deputy Director of the American Cancer Society's National Office, Just Lichtenfeld, he told the agency's blog that "It goes without saying that we all share the hope that they are the right ones",
"Unfortunately, we must realize that this is far from effective treatment of people with cancer, let alone medicine", he said.
Finally, the expert noted that Israeli scientists publicly did not show the data collected to support his announcement, in addition to not disclosing evidence that the treatment had been successful in mice, and specified that so far everything that was done was an interview with local media, according to site publimetro.cl,